Author

I. Hatial

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Bhardwaj· 1 shared B. Ashfeld· 1 shared B. Blagg· 1 shared D. Y. Maeda· 1 shared G. Huang· 1 shared H. A. Janabi· 1 shared J. Mittlesteadt· 1 shared J. Wan· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Bhardwaj

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Targeting Chromatin Effector Pygo2 to Enhance Immunotherapy in Prostate Cancer

Y. Zhu, Y. Zhao, J. Wen, S. Liu, T. Huang, I. Hatial, X. Peng, H. A. Janabi, G. Huang, J. Mittlesteadt, M. Cheng, A. Bhardwaj, B. Ashfeld, K. R. Kao, D. Y. Maeda, , X. Lu

This study identifies Pygo2 as a driver oncogene in prostate cancer that suppresses immune infiltration and response to immunotherapy, showing that its inhibition enhances anti-tumor immunity.

bioRxiv · Jun 16, 2022 · PreprintCancer Biology